Literature DB >> 11122988

Should the treatment of schizophrenia include old antipsychotic drugs?

R M Steel1, E C Johnstone.   

Abstract

Clozapine, although not suitable as a first-line drug, is superior to all other antipsychotics in terms of minimizing positive symptoms, reducing side effects, and treating treatment-resistant patients. There is little evidence that other newer drugs share these benefits. For certain patients it is not difficult to justify, on clinical grounds, the additional cost of prescribing clozapine. The case for prescribing one of the other newer drugs in preference to a traditional antipsychotic is often less clear-cut. Traditional antipsychotics clearly still have a role in the treatment of schizophrenia and they remain the authors' preferred choice of first-line therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122988     DOI: 10.1007/s11920-000-0023-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  12 in total

1.  Newer antipsychotics in treatment-resistant schizophrenia.

Authors:  S R Marder
Journal:  Biol Psychiatry       Date:  1999-02-15       Impact factor: 13.382

2.  PET studies of dopamine receptors in relation to antipsychotic drug treatment.

Authors:  L Farde; A L Nordström; C Halldin; F A Wiesel; G Sedvall
Journal:  Clin Neuropharmacol       Date:  1992       Impact factor: 1.592

3.  Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Authors:  R Rosenheck; L Dunn; M Peszke; J Cramer; W Xu; J Thomas; D Charney
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

4.  The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

Authors:  C H Miller; F Mohr; D Umbricht; M Woerner; W W Fleischhacker; J A Lieberman
Journal:  J Clin Psychiatry       Date:  1998-02       Impact factor: 4.384

5.  Treatment of negative symptoms.

Authors:  W T Carpenter; D W Heinrichs; L D Alphs
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Authors:  G Bondolfi; H Dufour; M Patris; J P May; U Billeter; C B Eap; P Baumann
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

8.  The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.

Authors:  R Mahmoud; L Engelhart; D Ollendorf; G Oster
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

9.  Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.

Authors:  A Breier; S H Hamilton
Journal:  Biol Psychiatry       Date:  1999-02-15       Impact factor: 13.382

10.  Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

Authors:  R W Buchanan; A Breier; B Kirkpatrick; P Ball; W T Carpenter
Journal:  Am J Psychiatry       Date:  1998-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.